March 22, 2007 — Edwards Lifesciences Corp. says it has received conditional FDA approval to initiate a pivotal clinical trial of the SAPIEN transcatheter aortic heart valve technology. The PARTNER (Placement of AoRTic traNscathetER valves) trial will evaluate the SAPIEN valve in patients who are considered high risk for conventional open-heart valve surgery.